Skip to content

Use of bioavailable form of Folic acid for Treatment of Depression

Role of L-Methylfolate in Treatment of Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008255
Enrollment
67
Registered
2017-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Depression

Interventions

Intervention1: L-Methylfolate,Escitalopram: Antidepressant Escitalopram: 10-20mg once daily oral dosage L-Methylfolate: 7.5-15mg once daily oral dosage Total duration of therapy: 8 weeks Control Inter

Sponsors

Director Principal Government medical college and hospital Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with primary diagnosis of moderate to severe depression according to ICD-10 DCR criteria. These patients should be treatment naïve or if receiving treatment should have regular compliance to it for at least 6 weeks and not be responding to the current treatment as defined by response of 2) Patients having HAM-D score of >=17, at time of intake which indicates at least moderate degree of depression. 3) Patient and his/her relative willing to give informed consent.

Exclusion criteria

Exclusion criteria: 1) Breastfeeding, and pregnant females 2) Having a current serious suicide risk, or psychotic symptoms 3) Unstable medical illness requiring concomitant use of other medication including those medications which are known to have depressogenic effect ( corticosteroids, anti-epileptics, beta-blockers, quinolone class of antibiotics, interferons, anti-neoplastic drugs). 4) Having an active substance use disorder within the past 6 months (in terms of fulfilling criteria for substance-harmful use or substance dependence) except nicotine and caffeine use. 5) Having past history of mania/hypomania (including antidepressant-induced), psychotic symptoms, or seizure disorder. 6) Taking vitamins or dietary supplements containing folate or vitamin B12. 7) Having comorbid diagnosis of intellectual disability, dementia, Alzheimerâ??s disease, or Parkinsonâ??s disease.

Design outcomes

Primary

MeasureTime frame
Change in HAM-D scoreTimepoint: 0,2,4,6,8 weeks

Secondary

MeasureTime frame
Change in quality of life and functioningTimepoint: 0,4,8 weeks

Countries

India

Contacts

Public ContactSushmita Bhattacharya

Government medical college and hospital, sector 32, Chandigarh

drchavanbs@gmail.com9646121611

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026